These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27038363)

  • 21. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
    Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
    Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
    [No Abstract]   [Full Text] [Related]  

  • 22. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inverse psoriasis treated with ustekinumab.
    Campos MA; Varela P; Baptista A; Moreira AI
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27222277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
    Dickson L; Menter A
    J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
    Bertrand V; El Haite A; Carré D
    Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.
    Garber C; Rosmarin D; Nguyen B; Goodarzi M; Shinagare S; Jessup C; Madani A; Au SC; Hasanain A
    Dermatol Online J; 2017 Mar; 23(3):. PubMed ID: 28329515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
    Menting SP; van den Reek JM; Baerveldt EM; de Jong EM; Prens EP; Lecluse LL; Wolbink GJ; Van der Kleij D; Spuls PI; Rispens T
    Br J Dermatol; 2015 Sep; 173(3):855-7. PubMed ID: 25865153
    [No Abstract]   [Full Text] [Related]  

  • 28. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
    Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
    Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
    [No Abstract]   [Full Text] [Related]  

  • 29. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.
    Rouse NC; Farhangian ME; Wehausen B; Feldman SR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):877-84. PubMed ID: 26488186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis.
    Raposo I; Bettencourt A; Leite L; Selores M; Torres T
    Acta Med Port; 2019 Mar; 32(3):214-218. PubMed ID: 30946793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in a solid organ transplanted recipient: A case report.
    Richetta A; Marraffa F; Grassi S; Aquila E; Dybala A; Aprile F; Merli M
    Australas J Dermatol; 2021 Aug; 62(3):e442-e443. PubMed ID: 33634474
    [No Abstract]   [Full Text] [Related]  

  • 34. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
    Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
    [No Abstract]   [Full Text] [Related]  

  • 35. Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus.
    Mazgaj M; Picard-Dahan C; Deschamps L; Marinho E; Estève E; Descamps V
    Int J Dermatol; 2020 Apr; 59(4):e118-e120. PubMed ID: 31957866
    [No Abstract]   [Full Text] [Related]  

  • 36. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
    Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
    Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
    [No Abstract]   [Full Text] [Related]  

  • 37. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    J Dermatolog Treat; 2019 Feb; 30(1):40-44. PubMed ID: 29676599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.
    Alsenaid A; Prinz JC
    J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):488-90. PubMed ID: 25413895
    [No Abstract]   [Full Text] [Related]  

  • 39. Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab.
    Goh SW; Jamil A; Nor NM; Cader RA; Shaharir SS
    Indian J Dermatol Venereol Leprol; 2020; 86(1):68-70. PubMed ID: 31823905
    [No Abstract]   [Full Text] [Related]  

  • 40. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.